Souhaitez-vous accéder aux communiqués récents ?

Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were...

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then...

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...

Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th

SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in...